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HIV can enter a state of latency that allows it to persist for decades in antiretroviral drug-treated patients. In a
recent Nature paper, Deng et al. (2015) show that this latent reservoir also contains a large number of cyto-
toxic T lymphocyte escape mutants, presenting another challenge to HIV cure efforts.Two prominent features of HIV infection
are its capacity to generate latent virus
and its ability evade the immune system
by rapidly mutating. A recent study by
Deng and coworkers has demonstrated
that these two characteristics are inter-
connected and that the latent reservoir is
heavily populated by viral genomes en-
coding cytotoxic T lymphocyte (CTL)
escape mutations (Deng et al., 2015).
Here, we discuss this important study
and its implications for efforts to eradicate
HIV from infected individuals.
HIV infects CD4+ T cells, and the
continuous destruction of these cells
over years leads to a weakened immune
system and to the development of AIDS.
High levels of HIV replication occur
throughout infection, generating billions
of new infected cells and free virions
each day, which are cleared by a fierce
immune response that includes HIV-spe-
cific CD8+ CTLs. This intense selection
pressure against the virus leads to the
selected outgrowth of viral CTL escape
variants, which are mutated in commonly
targeted CTL epitopes (Borrow et al.,
1997).
Antiretroviral therapy (ART) inhibits HIV
replication and prevents disease progres-
sion, but does not eliminate the virus
completely from infected patients, pri-
marily because of the presence of latently
infected resting CD4+ T cells (Chun et al.,
1997; Finzi et al., 1999). Latently infected
cells harbor HIV DNA within their chromo-
somes but express little or no viral RNA
and no viral proteins, rendering them
beyond the reach of ART and essentially
invisible to the immune system. However,
these cells can produce infectious virus if
they become stimulated; thus, they can
rekindle virus replication if a patient dis-
continues ART. Different methods for
depleting the latent reservoir have beenproposed (reviewed in Marsden and
Zack, 2013), but one strategy that is being
vigorously investigated is an activation-
elimination approach in which the host
cell is induced to express viral proteins,
allowing it to ideally be killed by viral cyto-
pathic effects or by the host immune
response. Various exogenous stimuli are
currently being tested in efforts to safely
and effectively activate latent HIV, but
some of these induce only low levels of
virus expression, which might not be suf-
ficient to kill the host cell without a robust
and effective immune response or other
therapeutic intervention (Marsden and
Zack, 2013; Shan et al., 2012).
In the study by Deng et al. (2015), the
authors compared HIV sequences from
resting CD4+ T cells in patients that
were treated with ART during the acute
phase of infection (within 3 months of
HIV infection) with those obtained from
patients who initiated therapy later during
the chronic phase of infection. This anal-
ysis revealed that known CTL escape var-
iants are rare in acute phase-treated
patients, but in contrast, nearly 100% of
the sequences from patients treated dur-
ing the chronic phase harbored CTL
escape mutations (Figure 1). Defective
HIV genomes tend to accumulate in
CD4+ cells over the course of infection,
meaning that most HIV DNA present in
resting CD4+ T cells is defective rather
than latent (Ho et al., 2013). Interestingly,
the authors also demonstrated that in
contrast to what is seen in individuals
treated early in infection, replication-
competent HIV induced from latently in-
fected cells from patients treated in the
chronic phase also bear a large number
of CTL resistance mutations. These data
suggest that unless ART is initiated very
early in the course of infection, the latent
reservoir becomes populated almostCell Host & Microbe 17,exclusively with variants resistant to
dominant CTL responses.
The presence of immunodominant CTL
escape mutations in some HIV epitopes
does not mean that other CTLs within
the patients that are specific for alterna-
tive epitopes are incapable of effectively
clearing virally infected cells. Therefore,
the authors investigated whether broad
peptide stimulation of CTLs from patients
treated in the chronic phase of infection
would allow the CTLs to kill cells infected
with autologous HIV derived from the
latent reservoir. Stimulation of the CTLs
with any one of several mixtures of pep-
tides corresponding to individual HIV
proteins resulted in improved killing of
HIV-infected cells. This was further inves-
tigated to show that only the CTLs tar-
geting different unmutated (wild-type)
epitopes, rather than CTL-escaped epi-
topes, efficiently eliminate autologous
infected CD4+ T cells. Hence, these pa-
tients retain CTL clones that can effec-
tively target unmutated HIV CTL epitopes
if the CTLs are stimulated with the appro-
priate peptide (Figure 1).
To validate that CTLs targeting unmu-
tated HIV epitopes can kill HIV-infected
cells in vivo, the authors utilized a human-
ized mouse model. In this model, a newly
generated immunodeficient mouse strain
termed MIS(KI)TRG was used as a recip-
ient for patient-derived hematopoietic
stem cells, which differentiated and
expanded to form a human immune sys-
tem within the mice. Autologous virus
from the latent reservoir of the same
patient was then injected into the mice.
After the infection was established, autol-
ogous CTLs that had been stimulated
with specific antigens were adoptively
transferred into the mice. In mice that
received control CTLs or CTLs stimulated
with a peptide corresponding to anFebruary 11, 2015 ª2015 Elsevier Inc. 141
Figure 1. CTL Escape Mutant Viruses in the Latent HIV Reservoir
(A) Soon after HIV transmission, latently infected CD4+ T cells contain HIV genomes encoding primarily
CTL-susceptible epitopes (green cells). However, these are replaced over time with viruses encoding
CTL escape mutations (red cells). Early initiation of antiretroviral therapy (ART) can prevent this accumu-
lation of resistant viruses.
(B) Upon expression of latent HIV, cells from patients that initiated ART early are susceptible to killing by
CTL specific for wild-type immunodominant HIV epitopes.
(C) HIV variants isolated from individuals treated later in infection (>3 months post-infection) are resistant
to killing by many CTLs that target common epitopes. Yet, these cells can still be killed by appropriately
stimulated CTLs specific for other non-mutated epitopes. Hence, elimination of the latent reservoir may
require both activation of latent virus expression and the stimulation of a broad CTL response.
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Previewsescaped epitope, the viral loads con-
tinued to increase; however, in mice
receiving CTL pre-stimulated with pep-
tides corresponding to other non-
mutated, wild-type epitopes, viral loads
were substantially reduced. Thus, CTL
clones targeting these unmutated epi-
topes were also effective at suppressing
virus replication in vivo.
This study has several important impli-
cations for our understanding of latent
HIV and efforts to eliminate the latent
reservoir. The fact that early initiation of
ART prevents the accumulation of CTL
escape mutant viruses in the latent HIV
reservoir provides another justification
for starting ART early to treat HIV infec-
tion. This is in addition to the already un-
derstood benefits of early treatment,
which include reducing the latent reser-142 Cell Host & Microbe 17, February 11, 201voir size and minimizing HIV-induced im-
mune system damage (Ananworanich
et al., 2012). This study also suggests
that efforts directed toward stimulating a
broader CTL response might be neces-
sary to kill cells induced to express latent
virus. The use of therapeutic vaccination
strategies, genetically engineered CTLs
that are pre-programmed with T cell re-
ceptors specific for these alternative HIV
epitopes, anti-HIV envelope immunotox-
ins (Brooks et al., 2003), or broadly
neutralizing antibodies (Halper-Strom-
berg et al., 2014) might also prove useful
in this regard.
Finally, the fact that the new CTL-resis-
tant viruses largely replaced the wild-type
virus in the latent reservoir is of great inter-
est and indicates that the latent reservoir
is more malleable than previously appre-5 ª2015 Elsevier Inc.ciated, at least in the early stages of infec-
tion. This suggests that the reservoir
could be substantially depleted if the nat-
ural rate of elimination of latently infected
cells in untreated infection could be main-
tained while preventing new formation of
latency with ART. This is essentially the
goal of activation-elimination approaches
and the focus of much current research.
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